The estimated Net Worth of Jerry S Lanchbury is at least $17.7 Million dollars as of 23 September 2021. Jerry Lanchbury owns over 200 units of Myriad Genetics stock worth over $7,582,174 and over the last 21 years he sold MYGN stock worth over $7,415,048. In addition, he makes $2,685,750 as Chief Scientific Officer at Myriad Genetics.
Sign up
Jerry Lanchbury MYGN stock SEC Form 4 insiders trading
Jerry has made over 52 trades of the Myriad Genetics stock since 2006, according to the Form 4 filled with the SEC. Most recently he sold 200 units of MYGN stock worth $7,012 on 23 September 2021.
The largest trade he's ever made was exercising 100,000 units of Myriad Genetics stock on 3 August 2021 worth over $2,599,000. On average, Jerry trades about 15,093 units every 57 days since 2003. As of 23 September 2021 he still owns at least 288,515 units of Myriad Genetics stock.
You can see the complete history of Jerry Lanchbury stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jerry Lanchbury biography
Dr. Jerry S. Lanchbury Ph.D., is the Chief Scientific Officer of Myriad Genetics, Inc. He joined the Company in September 2002 as Senior Vice President of Research. In July 2005 he was appointed Executive Vice President of Research, a position he held until he was named to his current position in February 2010. Dr. Lanchbury came to us from GKT School of Medicine, King’s College where he had served as Reader in Molecular Immunogenetics and Head of Molecular Immunogenetics Unit since 1997. Dr. Lanchbury earned his Ph.D. from the University of Newcastle upon Tyne and 1st Class Honours, B.Sc. “Biology of Man & his Environment” degree from the University of Aston.
What is the salary of Jerry Lanchbury?
As the Chief Scientific Officer of Myriad Genetics, the total compensation of Jerry Lanchbury at Myriad Genetics is $2,685,750. There are 2 executives at Myriad Genetics getting paid more, with R. Bryan Riggsbee having the highest compensation of $3,138,980.
How old is Jerry Lanchbury?
Jerry Lanchbury is 60, he's been the Chief Scientific Officer of Myriad Genetics since 2010. There are 11 older and 14 younger executives at Myriad Genetics. The oldest executive at Myriad Genetics, Inc. is Walter Gilbert, 87, who is the Independent Vice Chairman of the Board.
What's Jerry Lanchbury's mailing address?
Jerry's mailing address filed with the SEC is 320, Wakara Way, U of U Research Park, Salt Lake City, Salt Lake County, Utah, 84108, United States.
Insiders trading at Myriad Genetics
Over the last 22 years, insiders at Myriad Genetics have traded over $51,783,466 worth of Myriad Genetics stock and bought 61,160 units worth $1,252,955 . The most active insiders traders include Jerry S Lanchbury, Peter D Meldrum, and Arthur H Jr Hayes. On average, Myriad Genetics executives and independent directors trade stock every 18 days with the average trade being worth of $563,312. The most recent stock trade was executed by Heinrich Dreismann on 9 September 2024, trading 10,000 units of MYGN stock currently worth $270,500.
What does Myriad Genetics do?
myriad genetics inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. for more information on how myriad is making a difference, please visit the company's website: www.myriad.com.
What does Myriad Genetics's logo look like?
Complete history of Jerry Lanchbury stock trades at Myriad Genetics
Myriad Genetics executives and stock owners
Myriad Genetics executives and other stock owners filed with the SEC include:
-
R. Bryan Riggsbee,
Chief Financial Officer, Executive Vice President, Treasurer -
Bernard Tobin,
President - Myriad Autoimmune -
Jerry Lanchbury,
Chief Scientific Officer -
Paul J. Diaz,
CEO, Pres & Director -
R. Bryan Riggsbee,
Exec. VP, CFO & Treasurer -
Dr. Jerry S. Lanchbury Ph.D.,
Chief Scientific Officer -
Dr. Jerry S. Lanchbury,
Chief Scientific Officer -
Mark S. Verratti,
Pres of Myriad Neuroscience & Autoimmune -
Nicole Lambert,
Chief Operating Officer -
John Henderson,
Independent Director -
S. Louise Phanstiel,
Independent Chairman of the Board -
Dennis Langer,
Independent Director -
Heiner Dreismann,
Independent Director -
Lawrence Best,
Independent Director -
Walter Gilbert,
Independent Vice Chairman of the Board -
Daniel Spiegelman,
Independent Director -
Daniel Skovronsky,
Independent Director -
Colleen Reitan,
Independent Director -
Lee Newcomer,
Independent Director -
Rashmi Kumar,
Independent Director -
Mark Pollack,
Chief Medical Officer -
Gary King,
Executive Vice President - International Operations -
Benjamin Jackson,
Executive Vice President, General Counsel, Secretary -
Mark Verratti,
President - Myriad Neuroscience -
Ralph McDade,
President - Myriad RBM -
Nicole Lambert,
President - Myriad Oncology -
Paul Diaz,
President, Chief Executive Officer, Director -
Pamela Wong,
Chief Legal Officer -
Nathan Smith,
Sr. VP of Investor Relations & Treasury -
Dr. Kevin Richard Haas,
Chief Technology Officer -
Paul Chip Parkinson,
Exec. VP of Reimbursement Strategy -
Jayne Baird Hart,
Exec. VP of HR -
Dr. Clivetty Martinez,
Chief Compliance Officer -
Benjamin Jackson,
Exec. VP, Gen. Counsel & Sec. -
Scott Gleason,
Sr. VP of Investor Relations -
Kevin Richard Haas,
Chief Technology Officer -
Alexander Ford,
Chief Operating Officer -
Kevin Richard Haas,
Chief Technology Officer -
Heinrich Dreismann,
Director -
Richard Wenstrup,
Chief Medical Officer -
Virginia Drosos,
President Assurex Health -
Richard M Marsh,
V.P., General Counsel -
Mark Christopher Capone,
President & C.E.O. -
Samraat S. Raha,
Chief Operating Officer -
Pamela Wong,
Chief Legal Officer -
Walter Lloyd Sanders,
President Myriad Oncology -
Linda S Wilson,
Director -
Mark H Skolnick,
Chief Scientific Officer -
Gerald P. Belle,
Director -
Adrian N Hobden,
President -
W Wayne Laslie,
Chief Operating Officer, MPI -
Robert S Attiyeh,
Director -
Dale A Stringfellow,
Director -
Arthur Hull Jr Hayes,
Director -
Arthur H Jr Hayes,
Director -
William A Iii Hockett,
Vice President -
Gregory C Critchfield,
President -
Jay M Moyes,
Chief Financial Officer -
S George Simon,
Vice President -
Robert Gardner Harrison,
Chief Information Officer -
Ronald S. Rogers,
Exec VP Corp Communications -
James S Evans,
V.P. Finance -
T Craig Benson,
President, Myriad RBM -
Paul Bisaro,
Director -
Eric Santa,
Former Chief Growth Officer -
Paul Parkinson,
Fmr EVP Strategy & Innovation -
Margaret Ancona,
SVP, Chief of Staff -
Dale Muzzey,
Chief Scientific Officer -
Natalie Munk,
Chief Accounting Officer -
Heinrich Dreismann,
Director -
Jayne B. Hart,
See Remarks -
Shereen Solaiman,
Chief People Officer -
Scott J. Leffler,
Chief Financial Officer -
Jennifer Lynne Fox,
Chief Legal Officer